计划状态
活跃，非招募阶段
第 1 阶段 第二阶段允许先接受免疫治疗
没有CRC 指导的试验
是药物
Bevacizumab, capecitabine, LBL-007, Tislelizumab标签
MSS/ MMRp评论
For MSS CRC patients who are about to start first line of treatment in the metastatic setting (no prior chemo for metastatic cancer allowed). Patients with BRAF V600E mutated cancer are excluded from participation.
Standard of care (bevacizumab + fluoropyrimidine (5-FU or capecitabine)) vs different combinations/ different doses of two experimental agents, immunotherapies:
tislelizumab: anti PD-1, checkpoint inhbitor.
LBL-007: anti LAG-3 antibody (immunotherapy targeting human Lymphocyte-activation gene3 (LAG-3).
| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
Alaska Oncology and Hematology, Llc 阿拉斯加州安克拉治市 99508 |
活跃，非招募 |
|
Banner Md Anderson Cancer Center 亚利桑那州吉尔伯特 85234 |
活跃，非招募 |
|
Toi Clinical Research Cerritos, California 90703 |
活跃，非招募 |
|
Usc Norris Comprehensive Cancer Center (Nccc) 加利福尼亚州洛杉矶 90033 |
活跃，非招募 |
|
Valkyrie 临床试验 加利福尼亚州洛杉矶 90067 |
活跃，非招募 |
|
加利福尼亚大学洛杉矶分校 加利福尼亚州洛杉矶 90095 |
活跃，非招募 |
|
Hoag Memorial Presbyterian Newport, California 92663 |
活跃，非招募 |
|
Kaiser Permanente Northern California Vallejo, California 94510 |
活跃，非招募 |
|
Baptist Md Anderson Cancer Center Jacksonville, Florida 32207 |
活跃，非招募 |
|
Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana 46804 |
活跃，非招募 |
|
Baptist Health Lexington Lexington, Kentucky 40503 |
活跃，非招募 |
|
University of Kentucky Markey Cancer Center 肯塔基州列克星敦 40536 |
活跃，非招募 |
|
Norton Cancer Institute Louisville, Kentucky 40217 |
活跃，非招募 |
|
Pontchartrain Cancer Center Covington, Louisiana 70433 |
活跃，非招募 |
|
Ochsner Clinic Foundation New Orleans, Louisiana 70121 |
活跃，非招募 |
|
华盛顿大学医学院 St Louis, Missouri 63110 |
活跃，非招募 |
|
St Vincent Frontier Cancer Center 蒙大拿州比林斯 59102 |
活跃，非招募 |
|
内华达综合癌症中心 内华达州拉斯维加斯 89169 |
活跃，非招募 |
|
Cancer Care Specialists Reno, Nevada 89511 |
活跃，非招募 |
|
新墨西哥大学癌症中心 Albuquerque, New Mexico 87102 |
活跃，非招募 |
|
Perlmutter Cancer Center At Winthrop Oncology Hematology Associatesnyu Winthrop Hospital Mineola, New York 11501 |
活跃，非招募 |
|
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health 纽约州纽约市 10016 |
活跃，非招募 |
|
Columbia University Medical Center 纽约州纽约市 10032 |
活跃，非招募 |
|
Duke Cancer Center 北卡罗来纳州达勒姆 27710 |
活跃，非招募 |
|
University of Tennessee Medical Center Knoxville, Tennessee 37920 |
活跃，非招募 |
|
Ut Southwestern Medical Center 德克萨斯州达拉斯 75390 |
活跃，非招募 |
|
Ut Health San Antonio Mays Cancer Center 德克萨斯州圣安东尼奥 78229 |
活跃，非招募 |
|
弗吉尼亚癌症专科 弗吉尼亚州费尔法克斯 22031 |
活跃，非招募 |
|
Cancer Care Northwest Spokane Valley, Washington 99216 |
活跃，非招募 |
|
Multicare Health System Institute For Research and Innovation 华盛顿州塔科马 98405 |
活跃，非招募 |
| 澳大利亚 | |
|
Blacktown Cancer and Haematology Centre Blacktown, New South Wales 2148 |
活跃，非招募 |
|
Orange Health Service (Central West Cancer Care Centre) Orange, New South Wales 2800 |
活跃，非招募 |
|
Riverina Cancer Care Centre Wagga Wagga, New South Wales 2650 |
活跃，非招募 |
|
Calvary Mater Newcastle Waratah, New South Wales 2298 |
活跃，非招募 |
|
Pindara Private Hospital Benowa, Queensland 4217 |
活跃，非招募 |
|
Icon Cancer Centre South Brisbane South Brisbane, Queensland 4101 |
活跃，非招募 |
|
Flinders Centre For Innovation in Cancer (Fcic) Bedford Park, South Australia 5042 |
活跃，非招募 |
|
Lyell McEwin Hospital Elizabeth Vale, South Australia 5112 |
活跃，非招募 |
|
Monash Health Clayton, Victoria 3168 |
活跃，非招募 |
|
Austin Health 维多利亚州海德堡 3084 |
活跃，非招募 |
|
The Alfred Hospital 墨尔本，维多利亚州 3004 |
活跃，非招募 |
|
St John of God, Murdoch Murdoch, Western Australia 6150 |
活跃，非招募 |
|
One Clinical Research 西澳大利亚奈德兰兹 6009 |
活跃，非招募 |
| 中国 | |
|
The Second Hospital of Anhui Medical University Hefei, Anhui 230601 |
活跃，非招募 |
|
Peking University First Hospital Beijing, Beijing 100034 |
活跃，非招募 |
|
Beijing Tsinghua Changgung Hospital Beijing, Beijing 102218 |
活跃，非招募 |
|
Fujian Medical University Union Hospital Fuzhou, Fujian 350001 |
活跃，非招募 |
|
Quanzhou First Affliated Hospital of Fujian Medical University Quanzhou, Fujian 362000 |
活跃，非招募 |
|
厦门大学附属第一医院 福建厦门 361003 |
活跃，非招募 |
|
Gansu Provincial Hospital Lanzhou, Gansu 730000 |
活跃，非招募 |
|
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North) Guangzhou, Guangdong 510000 |
活跃，非招募 |
|
Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong 510000 |
活跃，非招募 |
|
The First Affiliated Hospital of Shantou University Medical College 广东汕头 515041 |
活跃，非招募 |
|
Nanyang Central Hospital Nanyang, Henan 473000 |
活跃，非招募 |
|
河南省肿瘤医院 Zhengzhou, Henan 450000 |
活跃，非招募 |
|
Hubei Cancer Hospital Wuhan, Hubei 430079 |
活跃，非招募 |
|
Hunan Cancer Hospital 湖南长沙 410013 |
活跃，非招募 |
|
The First Peoples Hospital of Changzhou Changzhou, Jiangsu 213000 |
活跃，非招募 |
|
Nantong First Peoples Hospital Nantong, Jiangsu 215124 |
活跃，非招募 |
|
Affiliated Hospital of Jiangnan University South Campus Wuxi, Jiangsu 214122 |
活跃，非招募 |
|
吉林大学第一医院 吉林长春 130021 |
活跃，非招募 |
|
General Hospital of Ningxia Medical University Yinchuan, Ningxia 750004 |
活跃，非招募 |
|
Shandong Cancer Hospital Jinan, Shandong 250117 |
活跃，非招募 |
|
Jining No.1 Peoples Hospital West Branch Jining, Shandong 272000 |
活跃，非招募 |
|
Linyi Peoples Hospital Linyi, Shandong 276000 |
活跃，非招募 |
|
Qingdao Municipal Hospital Qingdao, Shandong 266000 |
活跃，非招募 |
|
Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai 200000 |
活跃，非招募 |
|
Shanghai 10Th Peoples Hospital Shanghai, Shanghai 200072 |
活跃，非招募 |
|
Shanghai East Hospital Branch Hospital Shanghai, Shanghai 200123 |
活跃，非招募 |
|
Shanxi Provincial Cancer Hospital Taiyuan, Shanxi 030013 |
活跃，非招募 |
|
天津医科大学附属肿瘤医院 天津，天津 300060 |
活跃，非招募 |
|
Tianjin Union Medical Center (Nankai University Affiliated Hospital) Tianjin, Tianjin 300121 |
活跃，非招募 |
|
Karamay Central Hospital of Xinjiang Karamay, Xinjiang 834009 |
活跃，非招募 |
|
The Xinjiang Uygur Autonomous Region Peoples Hospital Urumqi, Xinjiang 830001 |
活跃，非招募 |
|
The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang 310009 |
活跃，非招募 |
| 波多黎各 | |
|
Pan American Oncology Trials, Llc Rio Piedras 00935 |
活跃，非招募 |
纳入标准
纳入标准
* Participant must have measurable disease as defined per RECIST version 1.1
* Has a histologically confirmed colorectal adenocarcinoma with metastatic or unresectable disease (Stage IV as defined by American Joint Committee on Cancer [AJCC] 8th edition)
* No prior systemic therapy for colorectal cancer (CRC) in the metastatic setting except for the induction treatment of first-line therapy. Note: Local regional treatment performed during induction systemic treatment is allowed
* Participants who have completed the first-line induction treatment, with an overall response of stable disease or better. The duration of induction treatment should be completed within approximately 6 months. The first dose of study treatment needs to occur within 2 weeks (for 2-week regimen) or 3 weeks (for 3-week regimen) to 6 weeks after Day 1 of the last cycle of induction therapy
排除标准
排除标准：
* Participants whose disease has become resectable at the investigator's discretion during or after induction treatment are not eligible
* Progressive disease occurred less than 6 months from completion of any prior neoadjuvant therapy (ie, chemotherapy with or without radiotherapy) or adjuvant therapy (ie, chemotherapy with or without radiotherapy), whichever occurred later
* Participants who have been treated with anti-epidermal growth factor receptor (EGFR) antibody in the induction treatment
* Any prior therapy targeting T-cell stimulation or checkpoint pathways
* Participants with B-raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutations
* Have locally or centrally confirmed microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR) method or dMMR by immunohistochemistry (IHC) method
Note: Other protocol defined criteria may apply.
